您的当前位置:首页 > 行业数据 > 707(PF’4404)在1LmCRC的临床3期研究方案
图片属性
图片格式:PNG 图片大小:667KB 图片尺寸:2244*753
同报告图片
 / 4
707(PF’4404)在1LmCRC的临床3期研究方案_第1页
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
707(PF’4404)在1LmCRC的临床3期研究方案_第2页
707(PF’4404)在1LmCRC的临床3期研究方案_第3页
707(PF’4404)在1LmCRC的临床3期研究方案_第4页
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
707(PF’4404)在1LmCRC的临床3期研究方案_第5页
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
所属报告: 三生制药(1530.HK)-港股公司研究报告:707联合化疗的临床2期数据公布即将开展两项关键3期临床研究-251112(9页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠